IDO and PD-L1 are essential for immune evasion and immune suppression, and downregulating these markers could enhance the immune system’s ability to recognize and attack tumor cells, thereby improving treatment efficacy [25,26]. This evidence concerns the gene IDO1 and neoplasm.